Citadel Advisors
MBVX

Citadel Advisors’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Citadel Advisors’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27,385
Closed -$23K – 10104
2018
Q2 		$23K Buy
+27,385
New +$34.7K ﹤0.01% 8619

Other funds holding MBVX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Citadel Advisors's MBVX Position: Q3 2018 in Review

Citadel Advisors sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 27,385 shares — an estimated $23K sold.

Citadel Advisors first reported a position in MBVX in Q2 2018 and held it in 1 quarter. The position peaked at $23K in Q2 2018. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

  • Citadel Advisors reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
  • Citadel Advisors sold 27,385 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018, an estimated $23K.
  • Citadel Advisors first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q2 2018 and held it in 1 quarter.
  • Citadel Advisors's MABVAX THERAPEUTICS HLDGS INC position peaked at $23K in Q2 2018.
  • 2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.